Publications by authors named "Ken Pienta"
Article Synopsis
- The study aims to compare different definitions of metastatic volume in metastatic castrate-sensitive prostate cancer (mCSPC) regarding patient outcomes and genetic mutations.
- A review of 294 patients showed that high-volume disease consistently had poorer outcomes in terms of overall survival (OS) and time to castration resistance (tdCRPC), regardless of which definition was used.
- Interestingly, 84.7% of patients maintained the same volume classification across definitions, but those with differing classifications displayed more aggressive disease behavior and mutations, particularly in TP53.
Landscapes play an important role in many areas of biology, in which biological lives are deeply entangled. Here we discuss a form of landscape in evolutionary biology which takes into account (1) initial growth rates, (2) mutation rates, (3) resource consumption by organisms, and (4) cyclic changes in the resources with time. The long-term equilibrium number of surviving organisms as a function of these four parameters forms what we call a success landscape, a landscape we would claim is qualitatively different from fitness landscapes which commonly do not include mutations or resource consumption/changes in mapping genomes to the final number of survivors.
View Article and Find Full Text PDFBackground: Integrins mediate invasion and angiogenesis in prostate cancer bone metastases. We conducted a phase II study of cilengitide, a selective antagonist of α(v)β(3) and α(v)β(5) integrins, in non-metastatic castration resistant prostate cancer with rising PSA.
Methods: Patients were observed for 4 weeks with PSA monitoring, and then treated with 2,000 mg IV of cilengitide twice weekly until toxicity/progression.